At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,053 enrolled
Drug / intervention
ezetimibe and atorvastatin +2 moredrug
Likely dose
ezetimibe and atorvastatin 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg When Added to Atorvastatin 10 mg Versus Titration to Atorvastatin 20 mg and to 40 mg in Elderly Patients With Hypercholesterolemia at High Risk for CHD
In Brief
A Phase 3 clinical trial evaluating ezetimibe and atorvastatin, atorvastatin, and 1 other intervention for Hypercholesterolemia. Completed, enrolled 1,053 participants.
Detailed Summary
A 12 week clinical trial in patients 65 years of age and older with hypercholesterolemia at high risk for coronary heart disease to study the effects of atorvastatin and ezetimibe given in combination and two higher doses of atorvastatin on lipid lowering.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
First PostedJan 2007
Primary CompletionOct 2008
TodayJul 2026
First PostedJan 5, 2007
Enrollment StartJan 1, 2007
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.5 years ago
Interventions
ezetimibe and atorvastatindrug
ezetimibe 10 mg and atorvastatin 10 mg daily for 12 weeks
atorvastatindrug
Atorvastatin 20 mg daily for 6 weeks, and up-titrated to atorvastatin 40 mg daily for an additional 6 weeks
Placebo (unspecified)drug
Placebo (unspecified) daily for 12 weeks